Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER_GOV × Breast Neoplasms × Irinotecan × Clear all

Phase

Status

Sponsor Class

OTHER 17 INDUSTRY 7 OTHER_GOV 1 NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Colorectal Neoplasms 10 Neoplasm Metastasis 6 Stomach Neoplasms 5 Small Cell Lung Carcinoma 2 Rectal Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Sarcoma 1 Recurrence 1 Lung Neoplasms 1 Gastrointestinal Neoplasms 1 Gastro-enteropancreatic neuroendocrine tumor 1 Colonic Neoplasms 1 Breast Neoplasms 1 Advanced Gastric Cancer Adenocarcinoma of Esophagogastric Junction 1

Interventions

Tamoxifen 9 Docetaxel 7 Trastuzumab 6 Letrozole 6 Gemcitabine 6 Exercise 6 Paclitaxel 5 Indocyanine Green 5 Cyclophosphamide 5 Control Groups 5 exemestane 4 Doxorubicin 4 Carboplatin 4 Capecitabine 4 Anastrozole 4 dalpiciclib 3 Vinorelbine 3 Standard of Care 3 Radiotherapy 3 Radiation 3 Mammography 3 Cisplatin 3 pyrotinib 2 pertuzumab 2 ferumoxides 2 Zoledronic Acid 2 Tablets 2 Surveys and Questionnaires 2 Surgical Procedures, Operative 2 Radiotherapy, Intensity-Modulated 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01501669 2012-07-18

PROCEED

National Cancer Center, Korea

Phase 3 Unknown

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡